<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2-6025-25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Arixtra 7.5mg-0.6ml Pre-filled syringe 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FONDAPARINUX SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        675.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN NOTRE DAM de BONDEVILLE" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN NOTRE DAM de BONDEVILLE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMACARE CANADA INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AX05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Arixtra is and what it is used for</strong><br /><strong>Arixtra&reg; is a medicine that treats or helps to prevent blood clots from forming in the blood vessels</strong> (an antithrombotic agent).<br />Arixtra&reg; contains a synthetic substance called fondaparinux sodium. This stops a clotting factor Xa (&ldquo;ten-A&rdquo;) from working in the blood, and so prevents unwanted blood clots (thromboses) from forming in the blood vessels.<br /><strong>Arixtra&reg; is used to treat adults with a blood clot in the blood vessels of their legs</strong> (deep vein thrombosis)<strong> and/or lungs </strong>(pulmonary embolism).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you use Arixtra&reg;</strong><br /><strong>Do not use Arixtra&reg;:<br />&bull; if you are allergic </strong>to fondaparinux sodium or to any of the other ingredients of this medicine (listed in section 6)<br /><strong>&bull; if you are bleeding excessively<br />&bull; if you have a bacterial heart infection<br />&bull; if you have severe kidney disease.</strong><br />➞ <strong>Tell your doctor </strong>if you think any of these applies to you. If they do, you must&nbsp;<strong>not</strong> use Arixtra&reg;.<br /><strong>Take special care with Arixtra&reg;:</strong><br />Talk to your doctor or pharmacist before taking Arixtra&reg;:<br />&bull;<strong> if you have previously had complications during treatment with heparin or heparin-like medicines causing a fall in the number of blood platelets (heparin-induced thrombocytopenia)</strong><br />&bull; <strong>if you have a risk of uncontrolled bleeding</strong> (haemorrhage) including:<br />▪<strong> stomach ulcer</strong><br />▪<strong> bleeding disorders</strong><br />▪ recent <strong>bleeding into the brain</strong> (intracranial bleeding)<br />▪ <strong>recent surgery</strong> on the brain, spine or eye<br />&bull;<strong> if you have severe liver disease</strong><br />&bull; <strong>if you have kidney disease</strong><br />&bull;<strong> if you are 75 years old or older.</strong><br />➞<strong> Tell your doctor</strong> if any of these applies to you.<br /><strong>Children and adolescents</strong><br />Arixtra&reg; has not been tested in children and adolescents under the age of 17 years.<br /><strong>Other medicines and Arixtra&reg;</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines you bought without a prescription. Some other medicines may affect the way that Arixtra&reg; works or be affected by Arixtra&reg;.<br /><strong>Pregnancy and breast-feeding</strong><br />Arixtra&reg; should not be prescribed to pregnant women unless clearly necessary.<br />Breast-feeding is not recommended during treatment with Arixtra&reg;. If you are <strong>pregnant</strong>, or <strong>breast-feeding</strong>, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<br /><strong>Arixtra&reg; contains sodium</strong><br />This medicinal product contains less than 23 mg of sodium in each dose and therefore is essentially sodium-free.<br /><strong>Arixtra&reg; syringe contains latex</strong><br />The syringe needle shield contains latex that has the potential to cause allergic reactions in latex sensitive individuals.<br />➞ <strong>Tell your doctor </strong>if you are allergic to latex before being treated with Arixtra&reg;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to use Arixtra&reg;</strong><br />Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Your weight</strong></p></td><td style="vertical-align:top"><p><strong>Usual dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Below 50 kg</p></td><td style="vertical-align:top"><p>5 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p>Between 50 kg and 100 kg</p></td><td style="vertical-align:top"><p>7.5 mg once a day</p></td></tr><tr><td style="vertical-align:top"><p>Over 100 kg</p></td><td style="vertical-align:top"><p>10 mg once a day.&nbsp; This dose may be reduced to 7.5 mg once a day if you have moderate kidney disease.</p></td></tr></tbody></table><p>You should inject at about the same time each day.<br /><strong>How Arixtra&reg; is given</strong><br />&bull; Arixtra&reg; is given by injection under the skin (subcutaneously) into a skin fold of the lower abdominal area. The syringes are pre-filled with the exact dose you need. There are different syringes for the 5 mg, 7.5 mg and 10 mg doses. <strong>For step-by-step instructions please see over the page.</strong><br />&bull; Do <strong>not </strong>inject Arixtra&reg; into muscle.<br /><strong>How long should Arixtra&reg; be taken for</strong><br />You should continue Arixtra&reg; treatment for as long as your doctor has told you,<br />since Arixtra&reg; prevents development of a serious condition.<br /><strong>If you inject too much Arixtra&reg;</strong><br />Contact your doctor or pharmacist for advice as soon as possible, because of the increased risk of bleeding.<br /><strong>If you forget to take Arixtra&reg;</strong><br />&bull; <strong>Take the dose as soon as you remember. Do not inject a double dose to make up for a forgotten dose.</strong><br />&bull; <strong>If you are not sure what to do</strong>, ask your doctor or pharmacist.<br /><strong>Don&rsquo;t stop using Arixtra&reg; without advice</strong><br />If you stop the treatment before your doctor told you to, the blood clot may not be treated properly, and you may also be at risk of developing a new blood clot in a vein of your leg or in the lung. <strong>Contact your doctor or pharmacist before stopping.</strong><br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong><br />Like all medicines, this medicine can cause side effects, although not everybody gets them.<br /><strong>Conditions you need to look out for</strong><br /><strong>Severe allergic reactions (anaphylaxis): </strong>These are very rare in people (up to 1 in 10,000) taking Arixtra&reg;. Signs include:<br />&bull; swelling, sometimes of the face or mouth (angioedema), causing difficulty in swallowing or breathing<br />&bull; collapse.<br />➞ <strong>Contact a doctor immediately</strong> if you get these symptoms. Stop taking <strong>Arixtra&reg;.</strong><br /><strong>Common side effects</strong><br />These may affect <strong>more than 1 in 100 people </strong>treated with Arixtra&reg;.<br />&bull; bleeding (for example from an operation site, an existing stomach ulcer, nose-bleed, bruising)<br /><strong>Uncommon side effects</strong><br />These may affect <strong>up to 1 in 100 people</strong> treated with Arixtra&reg;.<br />&bull; swelling (oedema)<br />&bull; headache<br />&bull; pain<br />&bull; feeling sick or being sick (nausea or vomiting)<br />&bull; low number of red blood cells (anaemia)<br />&bull; low number of platelets (blood cells necessary for blood clotting)<br />&bull; increase in some chemical (enzymes) produced by the liver<br /><strong>Rare side effects</strong><br />These may affect<strong> up to 1 in every 1000 people</strong> treated with Arixtra&reg;.<br />&bull; allergic reaction (including itching, swelling, rash)<br />&bull; internal bleeding in the brain, liver or abdomen<br />&bull; rash<br />&bull; dizziness<br />&bull; pain and swelling at injection site<br />&bull; high number of platelets (blood cells necessary for blood clotting)<br />&bull; increase in the amount of non-protein nitrogen in the blood<br />&bull; stomach pain<br />&bull; itching<br />&bull; indigestion<br />&bull; diarrhoea or constipation<br />&bull; increase in bilirubin (a substance produced by the liver) in the blood</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Arixtra&reg;</strong><br />&bull; Keep this medicine out of the sight and reach of children<br />&bull; Store below 25&deg;C. Do not freeze<br />&bull; Arixtra&reg; does not have to be kept in the fridge.<br /><strong>Do not use this medicine:</strong><br />&bull; after the expiry date shown on the label and carton<br />&bull; if you notice any particles in the solution, or if the solution is discoloured<br />&bull; if you notice that the syringe is damaged<br />&bull; if you have opened a syringe and you do not use it straightaway.<br /><strong>Disposal of syringes:</strong><br />Do not throw away any medicines or syringes via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no longer use . This will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Arixtra&reg; contains</strong><br />The active substance is:<br />&bull; 5 mg fondaparinux sodium in 0.4 ml solution for injection<br />&bull; 7.5 mg fondaparinux sodium in 0.6 ml solution for injection<br />&bull; 10 mg fondaparinux sodium in 0.8 ml solution for injection<br />The other ingredient(s) are sodium chloride, water for injections, and hydrochloric acid and/or sodium hydroxide to adjust the pH (see section 2).<br />Arixtra&reg; does not contain any animal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Arixtra® looks like and contents of the pack
Arixtra® is a clear and colourless to slightly yellow solution for injection. It is supplied in a pre-filled syringe fitted with a safety system to help prevent needle stick injuries after use.
It is available in packs of 2, 7, 10 and 20 pre-filled syringes (not all pack sizes may be marketed).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer<br />Marketing Authorisation Holder:</strong><br />Aspen Pharmacare Canada Inc.<br />Unit 8, 1155 North Service Road West,<br />Oakville, Ontario,<br />Canada, L6M 3E3</p><p><strong>Manufacturer:</strong><br />Aspen Notre Dame de Bondeville<br />1 rue de l&rsquo;Abbaye<br />F-76960 Notre Dame de Bondeville<br />France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in {September/2024}; version number {003}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. ما هو أريكسترا &reg; وما هي دواعي استخدامه</strong><br />أريكسترا &reg; دواء يعالج أو يساعد في منع تكوّن جلطات الدم في الأوعية الدموية (عامل مضاد للتخثر).</p><p>يحتوي أريكسترا &reg; على مادة اصطناعية تدعى صوديوم فوندابارينوكس. تمنع هذه المادة عامل التجلط (&quot;العاملالعاشر&quot;) من العمل في الدم، وبالتالي تمنع جلطات الدم غير المرغوبة (التخثرات) من التكوّن في الأوعية الدموية.</p><p>يُستخدم أريكسترا &reg; في علاج البالغين المصابين بجلطات الدم في الأوعية الدموية في سيقانهم (الخثار الوريدي العميق) و/أو الرئتين (الانصمام الرئوي).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. ما الذي تحتاج لمعرفته قبل استخدام أريكسترا &reg;</strong><br />لا يجب استخدام أريكسترا &reg;:<br />&bull; إذا كنت مصاباً بحساسية لمادة الصوديوم فوندابارينوكس أو لأي من مكونات الدواء الأخرى(المذكورة في القسم 6).<br />&bull; إذا كنت تنزف بشكل مفرط<br />&bull; إذا كنت مصاباً بعدوى بكتيرية في القلب<br />&bull; إذا كنت مصاباً بمرض كلوي حاد.<br />اخبر طبيبك إذا كنت تظن أن أي من هذه الأعراض ينطبق عليك. إذا كانت تنطبق عليك، ينبغي عليك الامتناع عن استخدام أريكسترا &reg;.</p><p>توخَ الحرص الشديد عند استخدام أريكسترا &reg;:<br />تحدث مع طبيبك أو الصيدلي قبل استخدام أريكسترا &reg; في الحالات التالية:<br />&bull; إذا سبق لك التعرض لمضاعفات أثناء العلاج بالهيبارين أو أدوية مشابهة له، مما تسبب في انخفاض عدد الصفائح الدموية (قلة الصفيحات المحفزة بالهيبارين)<br />&bull; إذا كنت معرضاً لاحتمال النزف غير المسيطر عليه (نزيف دموي) ويشمل ذلك:<br />▪ قرحة معدية<br />▪ اضطرابات نزفية<br />▪ نزيف حديث بالمخ (نزف داخل القحف)<br />▪ جراحة حديثة في المخ، أو العمود الفقري، أو العين<br />&bull; إذا كنت مصاباً بمرض كبدي حاد.<br />&bull; إذا كنت مصاباً بمرض كلوي.<br />&bull; إذا كنت تبلغ من العمر 75 عاماً أو أكثر.<br />تحدث إلى طبيبك إذا كنت تظن أن أي من هذه الأعراض ينطبق عليك.</p><p><strong>الأطفال والمراهقون</strong><br />لم يُختبر أريكسترا &reg; على الأطفال والمراهقين أقل من 17 عاماً.</p><p><strong>الأدوية الأخرى وأريكسترا &reg;</strong><br />أخبر طبيبك أو الصيدلي إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى . وهذا يشمل الأدوية التي يمكن شراؤها دون وصفة طبية. قد تؤثر بعض الأدوية الأخرى على الطريقة التي يعمل بها أريكسترا &reg; أو قد تتأثر به.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />يجب الامتناع عن وصف أريكسترا &reg; للسيدات الحوامل عدا في حالة الضرورة الواضحة. لا يوصى بالرضاعة الطبيعية خلال فترة العلاج بأريكسترا &reg;. إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، اطلبي المشورة من طبيبك أو الصيدلي قبل استعمال هذا الدواء .</p><p><strong>يحتوي أريكسترا &reg; على الصوديوم.</strong><br />يحتوي هذا المنتج الدوائي على أقل من 23 ملجم من الصوديوم في كل جرعة، أي أنه في الأساس خال من الصوديوم.</p><p><strong>محقن أريكسترا &reg; يحتوي على اللاتكس</strong><br />يحتوي غطاء إبرة المحقن على مادة اللاتكس التي يحتمل أن تتسبب في ردود فعل تحسسية لدى الأفراد المصابين بالحساسية من اللاتكس.<br />أخبر طبيبك إذا كنت مصاباً بالحساسية من مادة اللاتكس قبل تلقي العلاج بدواء أريكسترا</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. كيفية استخدام أريكسترا &reg;</strong><br />استخدم هذا الدواء دائماً على النحو الذي يصفه طبيبك أو الصيدلي بالضبط. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>وزنك.</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة المعتادة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أقل من 50 كجم</p></td><td style="vertical-align:top"><p dir="RTL">5 ملجم مرة يومياً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">بين 50 كجم و100 كجم</p></td><td style="vertical-align:top"><p dir="RTL">7.5 ملجم مرة يومياً</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أكثر من 100 كجم</p></td><td style="vertical-align:top"><p dir="RTL">10 ملجم مرة يومياً &nbsp;قد تخفض هذه الجرعة إلى 7.5 ملجم مرة يومياً إذا كنت مصاباً بمرض كلوي متوسط الدرجة.</p></td></tr></tbody></table><p>يجب أخذ الحقنة في نفس الوقت تقريباً كل يوم.</p><p>كيفية أخذ أريكسترا &reg;<br />&bull; يؤخذ أريكسترا &reg; عن طريق الحقن تحت الجلد في ثنية جلد في المنطقة أسفل البطن. المحاقن معبأة مسبقاً بالجرعة التي تحتاجها بالضبط. توجد محاقن مختلفة للجرعات 5 ملجم، و 7.5 ملجم، و 10 ملجم . للتعليمات خطوة بخطوة، يُرجى الاطلاع على الصفحة التالية.<br />&bull; لا تحقن أريكسترا &reg; في العضل.</p><p>كم تمتد فترة العلاج بدواء أريكسترا &reg;<br />ينبغي عليك المداومة على العلاج بدواء أريكسترا &reg; إلى المدة التي أخبرك بها الطبيب، حيث أنه يمنع الإصابة بحالات خطيرة.</p><p>في حالة الحقن بكمية أكبر مما ينبغي من أريكسترا &reg;<br />اتصل بطبيبك أو الصيدلي للمشورة في أقرب وقت ممكن، وذلك نظراً لارتفاع احتمال التعرض للنزيف.</p><p>إذا نسيت أخذ أريكسترا &reg;<br />&bull; خذ الجرعة بمجرد أن تتذكر. لا تحقن جرعة مضاعفة لتعويض الجرعة التي نسيتها.<br />&bull; إن لم تكن متأكداً مما يجب القيام به، اسأل طبيبك أو الصيدلي .</p><p>لا تنقطع عن استخدام أريكسترا &reg; بدون مشورة.<br />إذا انقطعت عن العلاج قبل أن يخبرك الطبيب بذلك، قد لا تعالج جلطة الدم على النحو المناسب وقد تتعرض لاحتمال تكوّن جلطة جديدة في الوريد في ساقك أو في الرئة. اتصل بطبيبك أو الصيدلي قبل إيقاف العلاج.</p><p>إن كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4. الآثار الجانبية المحتملة</strong><br />مثل جميع الأدوية يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.</p><p><strong>الحالات التي يجب عليك الانتباه لها</strong><br />ردود فعل تحسسية شديدة (التأق): شديدة الندرة في الأشخاص ( 1 من 10000 شخص) يُعالج بأريكسترا .&reg;<br />تتضمن الأعراض:<br />&bull; تورم، في بعض الأحيان في الوجه أو الفم (الوذمة الوعائية)، مما قد يتسبب في صعوبة البلع أو التنفس<br />&bull; الانهيار<br /><strong>اتصل بطبيبك على الفور إذا ظهرت عليك هذه الأعراض. توقف عن أخذ أريكسترا .&reg;</strong></p><p><strong>آثار جانبية شائعة</strong><br />قد تؤثر على أكثر من 1 من كل 100 شخص يُعالج بدواء أريكسترا &reg;<br />&bull; النزيف (على سبيل المثال من موضع جراحي، قرحة معدية حالية، نزيف من الأنف، كدمات)</p><p><strong>آثار جانبية غير شائعة</strong><br />قد تؤثر على 1 من كل 100 شخص يُعالج بدواء أريكسترا &reg;.<br />&bull; تورم (وذمة)<br />&bull; صداع<br />&bull; ألم<br />&bull; الشعور بالغثيان أو القيء<br />&bull; انخفاض عدد خلايا الدم الحمراء (أنيميا).<br />&bull; انخفاض عدد الصفائح الدموية (الخلايا الدموية الضرورية لتجلط الدم)<br />&bull; ارتفاع كمية المواد الكيميائية (الإنزيمات) التي ينتجها الكبد</p><p><strong>آثار جانبية نادرة</strong><br />قد تؤثر على 1 من كل 1000 شخص يُعالج بدواء أريكسترا &reg;.<br />&bull; ردود فعل تحسسية (تتضمن الحكة، والتورم، والطفح)<br />&bull; نزيف داخلي في المخ، أو الكبد، أو البطن<br />&bull; الطفح الجلدي<br />&bull; دوار<br />&bull; ألم وتورم في موضع الحقن<br />&bull; ارتفاع عدد الصفائح الدموية (الخلايا الدموية الضرورية لتجلط الدم)<br />&bull; ارتفاع في كمية النيتروجين اللا بروتيني في الدم<br />&bull; آلام بالمعدة<br />&bull; الحكة<br />&bull; عسر هضم<br />&bull; إسهال أو إمساك<br />&bull; ارتفاع البيليروبين (مادة ينتجها الكبد) في الدم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5. كيفية تخزين أريكسترا &reg;</strong><br />&bull; يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.<br />&bull; يخزن في درجة حرارة أقل من 25 درجة مئوية. لا تجمد هذا الدواء.<br />&bull; لا يلزم الاحتفاظ بدواء أريكسترا &reg; في البراد.</p><p><strong>لا تستخدم هذا الدواء:</strong><br />&bull; بعد تاريخ انتهاء الصلاحية الموضح على الملصق والعلبة الكرتونية<br />&bull; إذا لاحظت وجود أي جسيمات في المحلول، أو تغير لون المحلول<br />&bull; إذا لاحظت أن المحقن تالف.<br />&bull; إذا فتحت المحقن ولم تستخدمه على الفور.</p><p><strong>التخلص من المحاقن:</strong><br />لا تتخلص من أي أدوية أو حقن في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>محتويات أريكسترا &reg;</strong><br />المادة الفعالة هي:<br />&bull; 5 ملجم صوديوم فوندابارينوكس في 0.4 مل محلول للحقن<br />&bull; 7.5 ملجم صوديوم فوندابارينوكس في 0.6 مل محلول للحقن<br />&bull; 10 ملجم صوديوم فوندابارينوكس في 0.8 مل محلول للحقن</p><p>المكونات الأخرى هي كلوريد الصوديوم، ماء للحقن، وحمض الهيدروكلوريك و/أو هيدروكسيد الصوديوم لضبط درجة الحموضة(راجع القسم 2).</p><p>لا يحتوي أريكسترا &reg; على أي منتجات حيوانية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو أريكسترا &reg; وما هي محتويات العبوة</strong><br />أريكسترا &reg; محلول للحقن صاف تتراوح درجته ما بين عديم اللون إلى أصفر قليلاً. يورد في محقن معبأ مسبقاً مزود بنظام أمان يساعد في الحد من إصابات الإبرة بعد الاستخدام.<br />متوفر في عبوات تحتوي 2، و 7، و 10 ، و 20 محقن مسبق التعبئة(قد لا تكون جميع أحجام العبوات مسوقة في بلدك).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق التسويق والمُصَّنع</strong></p><p><strong>مالك حق التسويق:</strong><br />شركة أسبن فارماكير كندا<br />الوحدة 1155،8 طريق الخدمة الشمالية الغربية<br />أوكفيل، أونتاريو،<br />كندا، L6M 3E3</p><p><strong>المُصَّنع:</strong><br />أسبن نوتر دام دو بوندفيل<br />1 شارع دو لا بي<br />إف - 76960 نوتر دام دو بوندفيل<br />فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في {سبتمبر / 2024}، رقم النسخة {003}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arixtra 7.5 mg/0.6 ml solution for injection, pre-filled syringe.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each pre-filled syringe contains 7.5 mg of fondaparinux sodium in 0.6 ml solution for injection.
Excipient(s) with known effect: Contains less than 1 mmol of sodium (23 mg) per dose, and therefore is essentially sodium free.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
The solution is a clear and colourless to slightly yellow liquid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of adults with acute Deep Vein Thrombosis (DVT) and treatment of acute Pulmonary Embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />The recommended dose of fondaparinux is 7.5 mg (patients with body weight  50,  100kg) once daily administered by subcutaneous injection. For patients with body weight &lt; 50 kg, the recommended dose is 5 mg. For patients with body weight &gt; 100 kg, the recommended dose is 10 mg.</p><p>Treatment should be continued for at least 5 days and until adequate oral anticoagulation is established (International Normalised Ratio 2 to 3). Concomitant oral anticoagulation treatment should be initiated as soon as possible and usually within 72 hours. The average duration of administration in clinical trials was 7 days and the clinical experience from treatment beyond 10 days is limited.</p><p><u>Special populations</u><br />Elderly patients - No dosing adjustment is necessary. In patients 75 years, fondaparinux should be used with care, as renal function decreases with age (see section 4.4).</p><p>Renal impairment - Fondaparinux should be used with caution in patients with moderate renal impairment (see section 4.4).</p><p>There is no experience in the subgroup of patients with both high body weight (&gt;100 kg) and moderate renal impairment (creatinine clearance 30-50 ml/min). In this subgroup, after an initial 10 mg daily dose, a reduction of the daily dose to 7.5 mg may be considered, based on pharmacokinetic modelling (see section 4.4).</p><p>Fondaparinux should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.3).</p><p>Hepatic impairment - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment. In patients with severe hepatic impairment, fondaparinux should be used with care as this patient group has not been studied (see sections 4.4 and 5.2).</p><p>Paediatric population - Fondaparinux is not recommended for use in children below 17 years of age due to a lack of data on safety and efficacy (see sections 5.1 and 5.2).</p><p><u>Method of administration</u><br />Fondaparinux is administered by deep subcutaneous injection while the patient is lying down. Sites of administration should alternate between the left and the right anterolateral and left and right posterolateral abdominal wall. To avoid the loss of medicinal product when using the pre-filled syringe do not expel the air bubble from the syringe before the injection. The whole length of the needle should be inserted perpendicularly into a skin fold held between the thumb and the forefinger; the skin fold should be held throughout the injection.</p><p>For additional instructions for use and handling and disposal see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- active clinically significant bleeding
- acute bacterial endocarditis
- severe renal impairment defined by creatinine clearance < 30 ml/min.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fondaparinux is intended for subcutaneous use only. Do not administer intramuscularly.</p><p>There is limited experience from treatment with fondaparinux in haemodynamically unstable patients and no experience in patients requiring thrombolysis, embolectomy or insertion of a vena cava filter.</p><p>Haemorrhage</p><p>Fondaparinux should be used with caution in patients who have an increased risk of haemorrhage, such as those with congenital or acquired bleeding disorders (e.g. platelet count &lt;50,000/mm3), active ulcerative gastrointestinal disease and recent intracranial haemorrhage or shortly after brain, spinal or ophthalmic surgery and in special patient groups as outlined below.</p><p>As for other anticoagulants, fondaparinux should be used with caution in patients who have undergone recent surgery (&lt;3 days) and only once surgical haemostasis has been established.</p><p>Agents that may enhance the risk of haemorrhage should not be administered concomitantly with fondaparinux. These agents include desirudin, fibrinolytic agents, GP IIb/IIIa receptor antagonists, heparin, heparinoids, or Low Molecular Weight Heparin (LMWH). During treatment of VTE, concomitant therapy with vitamin K antagonist should be administered in accordance with the information of Section 4.5. Other antiplatelet medicinal products (acetylsalicylic acid, dipyridamole, sulfinpyrazone, ticlopidine or clopidogrel), and NSAIDs should be used with caution. If co-administration is essential, close monitoring is necessary.</p><p>Spinal / Epidural anaesthesia</p><p>In patients receiving fondaparinux for treatment of VTE rather than prophylaxis, spinal/epidural anaesthesia in case of surgical procedures should not be used.</p><p>Elderly patients</p><p>The elderly population is at increased risk of bleeding. As renal function generally decreases with age, elderly patients may show reduced elimination and increased exposure of fondaparinux (see section 5.2). Incidences of bleeding events in patients receiving the recommended regimen in the treatment of DVT or PE and aged &lt;65 years, 65-75 and &gt;75 years were 3.0 %, 4.5 % and 6.5 %, respectively. The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.5%, 3.6% and 8.3% respectively, while the incidences in patients receiving the recommended regimen of UFH in the treatment of PE were 5.5%, 6.6% and 7.4%, respectively. Fondaparinux should be used with caution in elderly patients (see section 4.2).</p><p>Low body weight</p><p>Clinical experience is limited in patients with body weight &lt;50 kg. Fondaparinux should be used with caution at a daily dose of 5 mg in this population (see sections 4.2 and 5.2).</p><p>Renal impairment<br />The risk of bleeding increases with increasing renal impairment. Fondaparinux is known to be excreted mainly by the kidney. Incidences of bleeding events in patients receiving the recommended regimen in the treatment of DVT or PE with normal renal function, mild renal impairment, moderate renal impairment and severe renal impairment were 3.0 % (34/1,132), 4.4 % (32/733), 6.6% (21/318), and 14.5 % (8/55) respectively. The corresponding incidences in patients receiving the recommended regimen of enoxaparin in the treatment of DVT were 2.3% (13/559), 4.6% (17/368), 9.7% (14/145) and 11.1% (2/18) respectively, and in patients receiving the recommended regimen of unfractionated heparin in the treatment of PE were 6.9% (36/523), 3.1% (11/352), 11.1% (18/162) and 10.7% (3/28), respectively.</p><p>Fondaparinux is contra-indicated in severe renal impairment (creatinine clearance &lt;30 ml/min) and should be used with caution in patients with moderate renal impairment (creatinine clearance 30-50 ml/min). The duration of treatment should not exceed that evaluated during clinical trial (mean 7 days) (see sections 4.2, 4.3 and 5.2).</p><p>There is no experience in the subgroup of patients with both high body weight (&gt;100 kg) and moderate renal impairment (creatinine clearance 30-50 ml/min). Fondaparinux should be used with care in these patients. After an initial 10 mg daily dose, a reduction of the daily dose to 7.5 mg may be considered, based on pharmacokinetic modelling (see section 4.2).</p><p>Severe hepatic impairment</p><p>The use of fondaparinux should be considered with caution because of an increased risk of bleeding due to a deficiency of coagulation factors in patients with severe hepatic impairment (see section 4.2).</p><p>Patients with Heparin Induced Thrombocytopenia<br />Fondaparinux should be used with caution in patients with a history of HIT. The efficacy and safety of fondaparinux have not been formally studied in patients with HIT type II. Fondaparinux does not bind to platelet factor 4 and does not usually cross-react with sera from patients with Heparin Induced Thrombocytopenia (HIT) type II. However, rare spontaneous reports of HIT in patients treated with fondaparinux have been received.</p><p>Latex Allergy<br />The needle shield of the pre-filled syringe contains dry natural latex rubber that has the potential to cause allergic reactions in latex sensitive individuals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bleeding risk is increased with concomitant administration of fondaparinux and agents that may enhance the risk of haemorrhage (see section 4.4).</p><p>In clinical studies performed with fondaparinux, oral anticoagulants (warfarin) did not interact with the pharmacokinetics of fondaparinux; at the 10 mg dose used in the interaction studies, fondaparinux did not influence the anticoagulation monitoring (INR) activity of warfarin.</p><p>Platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not interact with the pharmacokinetics of fondaparinux. At the 10 mg dose used in the interaction studies, fondaparinux did not influence the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the pharmacokinetics of digoxin at steady state.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />No clinical data on exposed pregnancies are available. Animal studies are insufficient with respect to effects on pregnancy, embryo/foetal development, parturition and postnatal development because of limited exposure. Fondaparinux should not be prescribed to pregnant women unless clearly necessary.</p><p>Breast-feeding<br />Fondaparinux is excreted in rat milk but it is not known whether fondaparinux is excreted in human milk. Breast-feeding is not recommended during treatment with fondaparinux. Oral absorption by the child is however unlikely.</p><p>Fertility<br />There are no data available on the effect of fondaparinux on human fertility. Animal studies do not show any effect on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and to use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported serious adverse reactions reported with fondaparinux are bleeding complications (various sites including rare cases of intracranial/ intracerebral and retroperitoneal bleedings). Fondaparinux should be used with caution in patients who have an increased risk of haemorrhage (see section 4.4).</p><p>The safety of fondaparinux has been evaluated in 2,517 patients treated for Venous Thrombo-Embolism and treated with fondaparinux for an average of 7 days. The most common adverse reactions were bleeding complications (see section 4.4).</p><p>The adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping (very common &ge;1/10; common: &ge;1/100 to &lt; 1/10; uncommon:&ge;1/1,000 to &lt; 1/100; rare: &ge; 1/10,000 to &lt;1/1,000; very rare &lt;1/10,000) and system organ class by decreasing order of seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class MedDRA</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions in patients treated for VTE<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td><td style="vertical-align:top"><p><em>Common: </em>bleeding (gastrointestinal, haematuria, haematoma, epistaxis, haemoptysis, utero-vaginal haemorrhage, haemarthrosis, ocular, purpura, bruise)</p><p><em>Uncommon: </em>anaemia, thrombocytopaenia</p><p><em>Rare: </em>other bleeding (hepatic, retroperitoneal, intracranial/intracerebral), thrombocythaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders</em></p></td><td style="vertical-align:top"><p><em>Rare: </em>allergic reaction (including very rare reports of angioedema, anaphylactoid/anaphylactic reaction)</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td><td style="vertical-align:top"><p><em>Rare: </em>non-protein-nitrogen (Npn) <sup>2</sup> increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top"><p><em>Uncommon</em>: headache</p><p><em>Rare: </em>dizziness</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top"><p><em>Uncommon: </em>nausea, vomiting</p><p><em>Rare: </em>abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top"><p><em>Uncommon</em>: abnormal liver function, hepatic enzymes increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p><em>Rare: </em>rash erythematous, pruritus</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top"><p><em>Uncommon: </em>pain, oedema,</p><p><em>Rare: </em>reaction at injection site</p></td></tr></tbody></table><p>(1) Isolated AEs have not been considered except if they were medically relevant.<br />(2) Npn stands for non-protein-nitrogen such as urea, uric acid, amino acid, etc.</p><p>In post marketing experience, rare cases of gastritis, constipation, diarrhoea and bilirubinaemia have been reported.</p><p><u>To report any side effect(s):</u></p><ul><li>&nbsp;Saudi Arabia:</li></ul><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>&bull;The National Pharmacovigilance Centre (NPC):<br />-SFDA Call Center: 19999<br />-E-mail: npc.drug@sfda.gov.sa<br />-Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>- Other GCC States:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>-Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fondaparinux doses above the recommended regimen may lead to an increased risk of bleeding.<br />There is no known antidote to fondaparinux.</p><p>Overdose associated with bleeding complications should lead to treatment discontinuation and search for the primary cause. Initiation of appropriate therapy such as surgical haemostasis, blood replacements, fresh plasma transfusion, plasmapheresis should be considered.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antithrombotic agents.<br />ATC code: B01AX05</p><p><u>Pharmacodynamic effects</u><br />Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa). The antithrombotic activity of fondaparinux is the result of antithrombin III (antithrombin) mediated selective inhibition of Factor Xa. By binding selectively to antithrombin, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by antithrombin. Neutralisation of Factor Xa interrupts the blood coagulation cascade and inhibits both thrombin formation and thrombus development. Fondaparinux does not inactivate thrombin (activated Factor II) and has no effects on platelets.</p><p>At the doses used for treatment, fondaparinux does not, to a clinically relevant extent, affect routine coagulation tests such as activated partial thromboplastin time (aPTT), activated clotting time (ACT) or prothrombin time (PT)/International Normalised Ratio (INR) tests in plasma nor bleeding time or fibrinolytic activity. However, rare spontaneous reports of aPTT prolongation have been received. At higher doses, moderate changes in aPTT can occur. At the 10 mg dose used in interaction studies, fondaparinux did not significantly influence the anticoagulation activity (INR) of warfarin.</p><p>Fondaparinux does not usually cross-react with sera from patients with heparin-induced thrombocytopaenia (HIT). However, rare spontaneous reports of HIT in patients treated with fondaparinux have been received.</p><p><u>Clinical studies</u><br />The fondaparinux clinical program in treatment of Venous Thromboembolism was designed to demonstrate the efficacy of fondaparinux for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Over 4,874 patients were studied in controlled Phase II and III clinical studies.</p><p>Treatment of Deep Venous Thrombosis<br />In a randomised, double-blind, clinical trial in patients with a confirmed diagnosis of acute symptomatic DVT, fondaparinux 5 mg (body weight &lt; 50 kg), 7.5 mg (body weight  50 kg,  100 kg) or 10 mg (body weight &gt;100 kg) SC once daily was compared to enoxaparin sodium 1 mg/kg SC twice daily. A total of 2,192 patients were treated; for both groups, patients were treated for at least 5 days and up to 26 days (mean 7 days). Both treatment groups received Vitamin K antagonist therapy usually initiated within 72 hours after the first study drug administration and continued for 90 &plusmn; 7 days, with regular dose adjustments to achieve an INR of 2-3. The primary efficacy endpoint was the composite of confirmed symptomatic recurrent non-fatal VTE and fatal VTE reported up to Day 97. Treatment with fondaparinux was demonstrated to be non-inferior to enoxaparin (VTE rates 3.9% and 4.1%, respectively).</p><p>Major bleeding during the initial treatment period was observed in 1.1% of fondaparinux patients, compared to 1.2% with enoxaparin.</p><p>Treatment of Pulmonary Embolism<br />A randomised, open-label, clinical trial was conducted in patients with acute symptomatic PE. The diagnosis was confirmed by objective testing (lung scan, pulmonary angiography or spiral CT scan). Patients who required thrombolysis or embolectomy or vena cava filter were excluded. Randomised patients could have been pre-treated with UFH during the screening phase but patients treated for more than 24 hours with therapeutic dose of anticoagulant or with uncontrolled hypertension were excluded. Fondaparinux 5 mg (body weight &lt; 50 kg), 7.5 mg (body weight  50kg,  100 kg) or 10 mg (body weight &gt;100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5&ndash;2.5 times aPTT control value. A total of 2,184 patients were treated; for both groups, patients were treated for at least 5 days and up to 22 days (mean 7 days). Both treatment groups received Vitamin K antagonist therapy usually initiated within 72 hours after the first study drug administration and continued for 90 &plusmn; 7 days, with regular dose adjustments to achieve an INR of 2-3. The primary efficacy endpoint was the composite of confirmed symptomatic recurrent non-fatal VTE and fatal VTE reported up to Day 97. Treatment with fondaparinux was demonstrated to be non-inferior to unfractionated heparin (VTE rates 3.8% and 5.0%, respectively).</p><p>Major bleeding during the initial treatment period was observed in 1.3% of fondaparinux patients, compared to 1.1% with unfractionated heparin.</p><p><strong>A pilot dose-finding and pharmacokinetic study of fondaparinux in children with deep vein thrombosis</strong><br />In an open-label study, 24 paediatric patients (n=10, age 1 to &le; 5 years weight range 8-20 kg; n=7, age 6 to &le; 12 years weight range 17-47 kg and n=7 age 13 to &le; 18 years weight range 47-130 kg) diagnosed with venous thrombosis at study entry were administered fondaparinux. The majority of patients were Hispanic (67%) and 58% were male. Fondaparinux was administered at an initial dose of 0.1 mg/kg subcutaneously once daily and dosing was adjusted to achieve peak fondaparinux sodium concentrations of 0.5 to 1 mg/L after 4 hours. The median duration of treatment in this study was 3.5 days. The majority of patients (88%) achieved target fondaparinux concentrations at 4 hours after the first dose of fondaparinux. Two patients had reports of bleeding during the study. One experienced hypertensive encephalopathy accompanied by intracranial bleeding on day 5 of therapy resulting in fondaparinux discontinuation. Minor gastrointestinal bleeding was reported in another patient on day 5 of therapy which resulted in temporary discontinuation of fondaparinux. No conclusion can be drawn with regard to clinical efficacy in this uncontrolled study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of fondaparinux sodium are derived from fondaparinux plasma concentrations quantified via anti factor Xa activity. Only fondaparinux can be used to calibrate the anti-Xa assay (the international standards of heparin or LMWH are not appropriate for this use). As a result, the concentration of fondaparinux is expressed as milligrams (mg).</p><p>Absorption<br />After subcutaneous dosing, fondaparinux is completely and rapidly absorbed (absolute bioavailability 100%). Following a single subcutaneous injection of fondaparinux 2.5 mg to young healthy subjects, peak plasma concentration (mean C<sub>max </sub>= 0.34 mg/l) is obtained 2 hours post-dosing. Plasma concentrations of half the mean C<sub>max </sub>values are reached 25 minutes post-dosing.</p><p>In elderly healthy subjects, pharmacokinetics of fondaparinux is linear in the range of 2 to 8 mg by subcutaneous route. Following once daily dosing, steady state of plasma levels is obtained after 3 to 4 days with a 1.3-fold increase in C<sub>max</sub> and AUC.</p><p>Mean (CV%) steady state pharmacokinetic parameters estimates of fondaparinux in patients undergoing hip replacement surgery receiving fondaparinux 2.5 mg once daily are: Cmax (mg/l) - 0.39 (31%), T<sub>max</sub> (h) - 2.8 (18%) and Cmin (mg/l) -0.14 (56%). In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are: C<sub>max</sub> (mg/l) - 0.50 (32%), C<sub>min</sub> (mg/l) - 0.19 (58%).</p><p>In DVT and PE treatment, patients receiving fondaparinux 5 mg (body weight &lt;50 kg), 7.5 mg (body weight 50-100 kg inclusive) and 10 mg (body weight &gt;100 kg) once daily, the body weight-adjusted doses provide similar exposure across all body weight categories. The mean (CV%) steady state pharmacokinetic parameters estimates of fondaparinux in patients with VTE receiving the fondaparinux proposed dose regimen once daily are: C<sub>max</sub> (mg/l) - 1.41 (23 %), T<sub>max</sub> (h) &ndash; 2.4 (8%) and C<sub>min</sub> (mg/l) -0.52 (45 %). The associated 5th and 95th percentiles are, respectively, 0.97 and 1.92 for C<sub>max</sub> (mg/l), and 0.24 and 0.95 for C<sub>min </sub>(mg/l).</p><p>Distribution<br />The distribution volume of fondaparinux is limited (7-11 litres). In vitro, fondaparinux is highly and specifically bound to antithrombin protein with a dose-dependant plasma concentration binding (98.6% to 97.0% in the concentration range from 0.5 to 2 mg/l). Fondaparinux does not bind significantly to other plasma proteins, including platelet factor 4 (PF4).</p><p>Since fondaparinux does not bind significantly to plasma proteins other than antithrombin, no interaction with other medicinal products by protein binding displacement are expected.</p><p>Biotransformation<br />Although not fully evaluated, there is no evidence of fondaparinux metabolism and in particular no evidence for the formation of active metabolites.<br />Fondaparinux does not inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4) in vitro. Thus, fondaparinux is not expected to interact with other medicinal products in vivo by inhibition of CYP-mediated metabolism.</p><p>Elimination<br />The elimination half-life (t&frac12;) is about 17 hours in healthy young subjects and about 21 hours in healthy elderly subjects. Fondaparinux is excreted to 64 &ndash; 77 % by the kidney as unchanged compound.</p><p><u>Special populations</u><br />Paediatric patients - Limited data are available in paediatric patients (see section 5.1).</p><p>Elderly patients - Renal function may decrease with age and thus, the elimination capacity for fondaparinux may be reduced in elderly. In patients &gt;75 years undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients &lt;65 years. A similar pattern is observed in DVT and PE treatment patients.</p><p>Renal impairment - Compared with patients with normal renal function (creatinine clearance &gt; 80 ml/min) undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, plasma clearance is 1.2 to 1.4 times lower in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min) and on average 2 times lower in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min). In severe renal impairment (creatinine clearance &lt;30 ml/min), plasma clearance is approximately 5 times lower than in normal renal function. Associated terminal half-life values were 29 h in moderate and 72 h in patients with severe renal impairment. A similar pattern is observed in DVT and PE treatment patients.</p><p>Body weight - Plasma clearance of fondaparinux increases with body weight (9% increase per 10 kg).</p><p>Gender - No gender differences were observed after adjustment for body weight.</p><p>Race - Pharmacokinetic differences due to race have not been studied prospectively. However, studies performed in Asian (Japanese) healthy subjects did not reveal a different pharmacokinetic profile compared to Caucasian healthy subjects. Similarly, no plasma clearance differences were observed between black and Caucasian patients undergoing orthopaedic surgery.</p><p>Hepatic impairment - Following a single, subcutaneous dose of fondaparinux in subjects with moderate hepatic impairment (Child-Pugh Category B), total (i.e., bound and unbound) C<sub>max</sub> and AUC were decreased by 22% and 39%, respectively, as compared to subjects with normal liver function. The lower plasma concentrations of fondaparinux were attributed to reduced binding to ATIII secondary to the lower ATIII plasma concentrations in subjects with hepatic impairment thereby resulting in increased renal clearance of fondaparinux. Consequently, unbound concentrations of fondaparinux are expected to be unchanged in patients with mild to moderate hepatic impairment, and therefore, no dose adjustment is necessary based on pharmacokinetics.<br />The pharmacokinetics of fondaparinux has not been studied in patients with severe hepatic impairment (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity. The repeated dose and reproduction toxicity studies did not reveal any special risk but did not provide adequate documentation of safety margins due to limited exposure in the animal species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1 List of excipients</strong></p><p>Sodium chloride<br />Water for injections<br />Hydrochloric acid<br />Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C. Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass barrel (1 ml) affixed with a 27 gauge x 12.7 mm needle and stoppered with a chlorobutyl elastomer plunger stopper.</p><p>Arixtra 7.5 mg/0.6 ml is available in pack sizes of 2, 7, 10 and 20 pre-filled syringes. There are two types of syringes:</p><ul><li>&nbsp;syringe with a magenta plunger and an automatic safety system</li><li>syringe with magenta plunger and a manual safety system.</li></ul><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The subcutaneous injection is administered in the same way as with a classical syringe.</p><p>Parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration.</p><p>Instruction for self-administration is mentioned in the Package Leaflet.</p><p>The Arixtra pre-filled syringes have been designed with a needle protection system to prevent needle stick injuries following injection.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>This medicinal product is for single use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharmacare Canada Inc.
Unit 8, 1155 North Service Road West,
Oakville, Ontario,
Canada, L6M 3E3
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                9/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>